These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 9446661

  • 1. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse.
    Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD, Reed JC.
    Blood; 1998 Feb 01; 91(3):991-1000. PubMed ID: 9446661
    [Abstract] [Full Text] [Related]

  • 2. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia.
    Hogarth LA, Hall AG.
    Blood; 1999 Apr 15; 93(8):2671-8. PubMed ID: 10194447
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M, Andreeff M, Ruvolo PP.
    Blood; 2015 Jul 16; 126(3):363-72. PubMed ID: 26045609
    [Abstract] [Full Text] [Related]

  • 4. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.
    Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, Rai K, Hines J, Reed JC.
    Blood; 1998 May 01; 91(9):3379-89. PubMed ID: 9558396
    [Abstract] [Full Text] [Related]

  • 5. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.
    Wuchter C, Karawajew L, Ruppert V, Büchner T, Schoch C, Haferlach T, Ratei R, Dörken B, Ludwig WD.
    Leukemia; 1999 Dec 01; 13(12):1943-53. PubMed ID: 10602414
    [Abstract] [Full Text] [Related]

  • 6. A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia.
    van Stijn A, Kok A, van der Pol MA, Feller N, Roemen GM, Westra AH, Ossenkoppele GJ, Schuurhuis GJ.
    Leukemia; 2003 Apr 01; 17(4):780-6. PubMed ID: 12682637
    [Abstract] [Full Text] [Related]

  • 7. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS, Bilardi RA, Ng AP, Xu Z, Robati M, Vandenberg CJ, Cory S.
    Cell Death Differ; 2019 Jul 01; 26(7):1316-1331. PubMed ID: 30470795
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma.
    Soini Y, Kinnula V, Kaarteenaho-Wiik R, Kurttila E, Linnainmaa K, Pääkkö P.
    Clin Cancer Res; 1999 Nov 01; 5(11):3508-15. PubMed ID: 10589765
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines.
    Nuessler V, Stötzer O, Gullis E, Pelka-Fleischer R, Pogrebniak A, Gieseler F, Wilmanns W.
    Leukemia; 1999 Nov 01; 13(11):1864-72. PubMed ID: 10557064
    [Abstract] [Full Text] [Related]

  • 13. Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells.
    Carter BZ, Mak PY, Tao W, Zhang Q, Ruvolo V, Kuruvilla VM, Wang X, Mak DH, Battula VL, Konopleva M, Jabbour EJ, Hughes PE, Chen X, Morrow PK, Andreeff M.
    Mol Cancer Ther; 2022 Jun 01; 21(6):879-889. PubMed ID: 35364607
    [Abstract] [Full Text] [Related]

  • 14. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.
    Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC, Byrd JC.
    J Clin Oncol; 2003 Apr 15; 21(8):1466-71. PubMed ID: 12697868
    [Abstract] [Full Text] [Related]

  • 15. Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML.
    O' Reilly E, Dhami SPS, Baev DV, Ortutay C, Halpin-McCormick A, Morrell R, Santocanale C, Samali A, Quinn J, O'Dwyer ME, Szegezdi E.
    Sci Rep; 2018 Oct 25; 8(1):15752. PubMed ID: 30361682
    [Abstract] [Full Text] [Related]

  • 16. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S, Dai Y, Harada H, Dent P, Grant S.
    Cancer Res; 2007 Jan 15; 67(2):782-91. PubMed ID: 17234790
    [Abstract] [Full Text] [Related]

  • 17. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Rosato RR, Almenara JA, Coe S, Grant S.
    Cancer Res; 2007 Oct 01; 67(19):9490-500. PubMed ID: 17909059
    [Abstract] [Full Text] [Related]

  • 18. The experimental and clinical study on the effect of curcumin on cell cycle proteins and regulating proteins of apoptosis in acute myelogenous leukemia.
    Chen Y, Wu Y, He J, Chen W.
    J Huazhong Univ Sci Technolog Med Sci; 2002 Oct 01; 22(4):295-8. PubMed ID: 12674762
    [Abstract] [Full Text] [Related]

  • 19. [Expression of survivin, Fas, bcl-2 and bax in bone marrow cells from acute myeloid leukemia patients and its clinical significance].
    Lin FR, Wang Y, Wang RQ, Du XY, Guo XN, Ren JH, Guo XL, Yao L, Yao EG.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun 01; 11(3):259-62. PubMed ID: 12844408
    [Abstract] [Full Text] [Related]

  • 20. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.
    Puthier D, Derenne S, Barillé S, Moreau P, Harousseau JL, Bataille R, Amiot M.
    Br J Haematol; 1999 Nov 01; 107(2):392-5. PubMed ID: 10583232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.